Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
In patients with ER+/HER2- metastatic breast cancer and selected genomic alterations, this triplet combination was active and had an acceptable toxicity profile (NCT04053322).
Authors
- Audrey Mailliez (ORCID: https://orcid.org/0000-0002-0475-8631)
- Étienne Brain (ORCID: https://orcid.org/0000-0003-0881-9371)
- Anthony Gonçalvès (ORCID: https://orcid.org/0000-0001-7570-7439)
- Pablo Lemercier (ORCID: https://orcid.org/0000-0003-1722-8303)
- François P. Duhoux (ORCID: https://orcid.org/0000-0002-5429-7888)
- Clara Guyonneau (ORCID: https://orcid.org/0009-0001-4560-4233)
- Séverine Guiu (ORCID: https://orcid.org/0000-0002-4901-6295)
- Jean‐Sébastien Frenel (ORCID: https://orcid.org/0000-0002-5273-0561)
- Thomas Bachelot (ORCID: https://orcid.org/0000-0002-0866-9484)
- Camille Chakiba (ORCID: https://orcid.org/0000-0002-6383-9589)
- Louise-Marie Chevalier (ORCID: https://orcid.org/0000-0002-2101-4749)
- Florence Dalenc (ORCID: https://orcid.org/0000-0002-9854-4182)
- Isabel Pimentel (ORCID: https://orcid.org/0000-0003-2128-7197)
- Elsa Curtit (ORCID: https://orcid.org/0000-0003-4814-8680)
- Fanny Derquin (ORCID: https://orcid.org/0009-0002-4462-8150)
- Jérôme Lemonnier (ORCID: https://orcid.org/0000-0002-8821-2168)
- Frédéric Bigot (ORCID: https://orcid.org/0000-0001-5890-107X)
- Suzette Delaloge (ORCID: https://orcid.org/0000-0003-2106-9165)
- Judith Balmañà (ORCID: https://orcid.org/0000-0002-0762-6415)
- Olfa Derbel (ORCID: https://orcid.org/0009-0003-6150-152X)
- Adrien Buisson (ORCID: https://orcid.org/0000-0002-8924-7776)
- Jean-Luc Canon (ORCID: https://orcid.org/0009-0000-3016-9323)
- Philippe Follana (ORCID: https://orcid.org/0000-0001-6999-462X)
Institutions
- Hebron University (PS)
- Centre National de la Recherche Scientifique (FR)
- Cliniques Universitaires Saint-Luc (BE)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Hôpital René Huguenin (FR)
- Hôpital Privé Jean Mermo (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Claudius Regaud (FR)
- Centre Oscar Lambret (FR)
- Institut Bergonié (FR)
- Arcagy Gineco (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- UniCancer Group (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
- Centre Antoine Lacassagne (FR)
- Grand Charleroi Hospital (BE)
- Institut Regional du Cancer de Montpellier (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4221
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09